Novamind (NM) partnered with Bienstar Wellness to develop the first network of integrative mental health clinics in Latin America. The companies plan to bring psychedelic medicine to Uruguay, Brazil, Mexico, Peru, and Panama.
Researchers from leading universities around the globe are joining forces to make psychedelic medicine a reality.
This Friday, a $40 million psychedelic research institute called The Psychae Institute will launch in Melbourne, Australia. The institute will study psilocybin, MDMA, and DMT to develop pharmaceutical-grade psychedelic medicines, and will oversee clinical studies in the UK, Canada, Europe, and Brazil. A co-director of the institute explains that Australia is the ideal location because clinical trials do not need sign-off from an ethics committee, unlike many countries.
